Federation des caisses Desjardins du Quebec’s Trevi Therapeutics TRVI Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$51.3K	Buy	+4,300	New	+$48.1K	﹤0.01%	1854

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's TRVI Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec opened a new position in Trevi Therapeutics (TRVI) in Q1 2026: 4,300 shares worth $51.3K. The stake represents ﹤0.01% of the portfolio and ranks #1854 among its holdings.

198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Federation des caisses Desjardins du Quebec held 4,300 shares of Trevi Therapeutics worth $51.3K as of Q1 2026.
Trevi Therapeutics was a new Federation des caisses Desjardins du Quebec position in Q1 2026.
Trevi Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #1854 holding.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.